GALNT18

Across TCGA pan-cancer cohorts, GALNT18 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GALNT18 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GALNT18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GALNT18 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, PRAD, and COAD are the cancer types where GALNT18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →
LIHC	OS	Median	All	0.164	0.688	.030	6	view →
GBM	DFS	Median	All	1.000	0.248	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GALNT18–LUAD (OS)

Open the LUAD breakdown →